NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) had its target price reduced by research analysts at Ascendiant Capital Markets from $8.00 to $0.85 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target suggests a potential upside of 8.96% from the company’s current price.
Separately, StockNews.com initiated coverage on NovaBay Pharmaceuticals in a research note on Saturday. They issued a “hold” rating for the company.
View Our Latest Analysis on NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Stock Up 10.6 %
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative return on equity of 744.33%. Equities research analysts anticipate that NovaBay Pharmaceuticals will post -1.41 EPS for the current year.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- Stock Dividend Cuts Happen Are You Ready?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What are earnings reports?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.